Seeking Alpha

ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)

PRINCETON, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANIP) today announced results from the NEW DAY clinical trial of ILUVIEN® (fluocinolone acetonide intravitreal implant), 0 ...
Nasdaq

ANI Pharmaceuticals Presents NEW DAY Trial Results: Evaluating ILUVIEN's Efficacy in Diabetic Macular Edema Treatment at ASRS Meeting

ANI Pharmaceuticals announced the results of the NEW DAY clinical trial for ILUVIEN® (fluocinolone acetonide) in diabetic macular edema (DME) patients during the ASRS Annual Scientific Meeting. The ...
Seeking Alpha

ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label

ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to diabetic macular edema (DME) ANI plans to begin marketing ...
Business Insider

Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign to Raise Awareness and Educate Consumers on Diabetic Macular Edema and ILUVIEN®

Pilot program to be initiated in four U.S. cities leveraging radio, print and social media channels, with potential for future expansion ILUVIEN’s CONTINUOUS MICRODOSING™ delivery enables patients ...
Healio

Retina experts reach consensus on inflammation and Iluvien in DME

Please provide your email address to receive an email when new articles are posted on . Consensus statements provide useful guidance on current clinical practice patterns and disease pathophysiology ...
Business Insider

Alimera’s ILUVIEN® Receives Positive NICE Recommendation for Non-Infectious Posterior Uveitis

ATLANTA, June 20, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the ...